Q-omics provides the consensus-scored GPR152 profile across patient tissues and cancer cell-line models. GPR152 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, GPR152 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, GPR152 RNA expression shows 11,438 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LGG, HNSC, and THYM as cancer lineages where GPR152 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR152 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR152 survival associations across molecular data types. GPR152 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR152 RNA expression–survival associations across cancer types. High GPR152 expression shows unfavorable associations in LGG, COAD, TGCT and KIRC, but favorable associations in SCLC and SKCM. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for GPR152 RNA expression.
This table summarizes GPR152 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR152. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR152 shows lower tumor expression in KICH and higher tumor expression in HNSC, PRAD, KIRP, STAD and COAD. The HNSC box plot shows higher GPR152 RNA expression in tumor versus normal tissue (log2 FC = +0.023, t-test p = .006).
This table shows molecular features associated with GPR152 in patient tissues and cancer cell lines. In patient samples, GPR152 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR152 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
